Intellia Q4 net loss $113.4M, cash $1.3B; NTLA-2002 Phase 2 started, NTLA-2001 pivotal plan on track

Intellia Therapeutics, Inc.

2022-FY EPS reported -$6.16 revenue$52,121,000

Q4 2022 net loss $113.4M vs $81.2M YoY; R&D expenses rose to $100.0M from $71.2M.
Cash, equivalents and marketable securities $1.3B as of Dec 31, 2022, up from $1.1B.
Initiated global Phase 2 study of NTLA-2002 for HAE; submitted IND to FDA for U.S. enrollment.
Plan to submit IND for NTLA-2001 in ATTR-CM in mid-2023; global pivotal trial expected by year-end 2023.
IND-enabling activities for NTLA-3001 (AATD lung) with filing planned in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.

Period: quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-003940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.